218 related articles for article (PubMed ID: 23677535)
1. Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic.
Petzel SV; Vogel RI; Bensend T; Leininger A; Argenta PA; Geller MA
J Genet Couns; 2013 Oct; 22(5):662-73. PubMed ID: 23677535
[TBL] [Abstract][Full Text] [Related]
2. Uptake of testing for germline
Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
[TBL] [Abstract][Full Text] [Related]
3. Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system.
Petzel SV; Vogel RI; McNiel J; Leininger A; Argenta PA; Geller MA
Int J Gynecol Cancer; 2014 Jul; 24(6):1003-9. PubMed ID: 24887442
[TBL] [Abstract][Full Text] [Related]
4. Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
Burling MJ; Gamet K; Eva L; Tan AL
Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):444-449. PubMed ID: 30883681
[TBL] [Abstract][Full Text] [Related]
5. Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
Swanson CL; Kumar A; Maharaj JM; Kemppainen JL; Thomas BC; Weinhold MR; Slaby KM; Mara KC; Wick MJ; Bakkum-Gamez JN
Gynecol Oncol; 2018 Apr; 149(1):121-126. PubMed ID: 29402500
[TBL] [Abstract][Full Text] [Related]
6. Genetic counseling referral for ovarian cancer patients: a call to action.
Garcia C; Harrison K; Ring KL; Sullivan MW; Rauh LA; Modesitt SC
Fam Cancer; 2019 Jul; 18(3):303-309. PubMed ID: 30993488
[TBL] [Abstract][Full Text] [Related]
7. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N
Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053
[TBL] [Abstract][Full Text] [Related]
8. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
[TBL] [Abstract][Full Text] [Related]
9. Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
Boitano TKL; Barrington DA; Batra S; McGwin G; Turner TB; Farmer MB; Brown AM; Straughn MJ; Leath CA
Gynecol Oncol; 2019 Aug; 154(2):379-382. PubMed ID: 31196574
[TBL] [Abstract][Full Text] [Related]
10. [A survey of willingness about genetic counseling and tests in patients of epithelial ovarian cancer].
Li L; Qiu L; Wu M
Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(43):3412-3415. PubMed ID: 29179283
[No Abstract] [Full Text] [Related]
11. Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
Uyar D; Neary J; Monroe A; Nugent M; Simpson P; Geurts JL
Gynecol Oncol; 2018 Jun; 149(3):565-569. PubMed ID: 29653687
[TBL] [Abstract][Full Text] [Related]
12. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH
Gynecol Oncol; 2017 Aug; 146(2):399-404. PubMed ID: 28610746
[TBL] [Abstract][Full Text] [Related]
13. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
14. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
[TBL] [Abstract][Full Text] [Related]
15. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
[TBL] [Abstract][Full Text] [Related]
16. Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system.
Bellcross CA; Peipins LA; McCarty FA; Rodriguez JL; Hawkins NA; Hensley Alford S; Leadbetter S
Genet Med; 2015 Jan; 17(1):43-50. PubMed ID: 24946155
[TBL] [Abstract][Full Text] [Related]
17. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
Kentwell M; Dow E; Antill Y; Wrede CD; McNally O; Higgs E; Hamilton A; Ananda S; Lindeman GJ; Scott CL
Gynecol Oncol; 2017 Apr; 145(1):130-136. PubMed ID: 28162234
[TBL] [Abstract][Full Text] [Related]
18. Universal access to genetic counseling for women with epithelial ovarian cancer in Nova Scotia: Evaluating a new collaborative care model.
Warias A; Ferguson M; Chamberlain E; Currie L; Snow N; Matheson K; Penney LS; Kieser K
J Genet Couns; 2021 Oct; 30(5):1491-1499. PubMed ID: 33876505
[TBL] [Abstract][Full Text] [Related]
19. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
[TBL] [Abstract][Full Text] [Related]
20. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA
Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
